HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation

Lignende værker

• Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
  af: Cao, Yaqing, et al.
  Udgivet: (2019)
• Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma
  af: Kanakry, Jennifer A., et al.
  Udgivet: (2013)
• Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies
  af: Zhang, Fei, et al.
  Udgivet: (2013)
• Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
  af: He, Xiaoyuan, et al.
  Udgivet: (2019)
• HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation
  af: Zeidan, Amer M, et al.
  Udgivet: (2013)